HEOR

News

NICE backs first disease-modifying drug for ARG1 deficiency

Immedica's Loargys is poised to become the first NHS therapy for ultra-rare genetic disorder ARG1 deficiency that can alter the course of the disease.

News

Abbott's wireless heart failure sensor cleared for NHS use

A wireless sensor the size of a paperclip, Abbott's CardioMEMS HF, can now be used routinely by the NHS to monitor patients with heart failure.

News

COPD patients will get access to Dupixent via NHS

Almost 30,000 people in England with COPD stand to get access to Dupixent, the first biologic for the devastating disease, after NICE backs its use.

News

Change of heart as NICE backs prostate cancer drug Talzenna

Thousands of men with prostate cancer will be offered a new treatment, Pfizer's Talzenna, after NICE made an about-turn on the drug.

News

NICE backs Roche lupus drug that supports kidney function

Roche's Gazyvaro, a drug that can restore kidney function in lupus nephritis, has been cleared for use by the NHS in England and Wales.

News

HCP with a small pile of pills in their palm

NICE relents, ending postcode access to prostate cancer drug

Men in England with high-risk prostate cancer will soon be able to get treatment with a drug available in Scotland and Wales for almost three years.

NICE backs first disease-modifying drug for ARG1 deficiency

Abbott's wireless heart failure sensor cleared for NHS use

COPD patients will get access to Dupixent via NHS

Change of heart as NICE backs prostate cancer drug Talzenna

NICE backs Roche lupus drug that supports kidney function

NICE relents, ending postcode access to prostate cancer drug

Novo sues Lilly over 'misleading' GLP-1 ad campaigning

Discover a new era of healthcare panel engagement: Grounded ...

HEOR

Editor's Picks